Q2 2022 EPS Estimates for Inozyme Pharma, Inc. Boosted by Wedbush (NASDAQ:INZY)

Inozyme Pharma, Inc. (NASDAQ:INZYGet Rating) – Stock analysts at Wedbush upped their Q2 2022 earnings per share estimates for Inozyme Pharma in a research note issued on Tuesday, May 10th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($0.43) per share for the quarter, up from their prior estimate of ($0.53). Wedbush currently has a “Outperform” rating and a $23.00 target price on the stock. Wedbush also issued estimates for Inozyme Pharma’s Q3 2022 earnings at ($0.48) EPS, Q4 2022 earnings at ($0.37) EPS, FY2022 earnings at ($1.85) EPS, Q1 2023 earnings at ($0.41) EPS, Q2 2023 earnings at ($0.44) EPS, Q3 2023 earnings at ($0.48) EPS, Q4 2023 earnings at ($0.52) EPS, FY2023 earnings at ($1.85) EPS, FY2024 earnings at ($0.70) EPS and FY2025 earnings at ($2.07) EPS.

Other equities research analysts have also recently issued reports about the company. HC Wainwright began coverage on Inozyme Pharma in a research report on Monday, February 7th. They issued a “buy” rating and a $33.00 price objective for the company. Needham & Company LLC assumed coverage on Inozyme Pharma in a report on Thursday, April 14th. They set a “buy” rating and a $23.00 price objective for the company.

NASDAQ:INZY opened at $4.00 on Friday. Inozyme Pharma has a 52 week low of $3.54 and a 52 week high of $19.58. The stock’s 50 day moving average price is $4.36 and its 200 day moving average price is $6.34. The company has a market capitalization of $95.28 million, a P/E ratio of -1.52 and a beta of 1.12.

Inozyme Pharma (NASDAQ:INZYGet Rating) last released its quarterly earnings data on Tuesday, May 10th. The company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.11.

In related news, Director Robert Lorne Hopfner bought 1,070,000 shares of Inozyme Pharma stock in a transaction on Tuesday, April 19th. The shares were purchased at an average price of $3.69 per share, for a total transaction of $3,948,300.00. Following the completion of the acquisition, the director now owns 2,661,154 shares in the company, valued at $9,819,658.26. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, COO Henric Bjorn Bjarke bought 27,100 shares of Inozyme Pharma stock in a transaction on Tuesday, April 19th. The shares were bought at an average price of $3.69 per share, for a total transaction of $99,999.00. Following the acquisition, the chief operating officer now owns 80,626 shares of the company’s stock, valued at approximately $297,509.94. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 2,519,850 shares of company stock valued at $9,298,247. Corporate insiders own 11.29% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of INZY. Citigroup Inc. lifted its holdings in shares of Inozyme Pharma by 241.6% during the 1st quarter. Citigroup Inc. now owns 12,517 shares of the company’s stock valued at $51,000 after purchasing an additional 8,853 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Inozyme Pharma by 16,531.3% during the 4th quarter. Wells Fargo & Company MN now owns 7,983 shares of the company’s stock valued at $54,000 after purchasing an additional 7,935 shares in the last quarter. Bank of America Corp DE lifted its holdings in shares of Inozyme Pharma by 4,030.0% during the 4th quarter. Bank of America Corp DE now owns 11,853 shares of the company’s stock valued at $81,000 after purchasing an additional 11,566 shares in the last quarter. Walleye Capital LLC bought a new position in shares of Inozyme Pharma during the 4th quarter valued at about $106,000. Finally, New York State Common Retirement Fund lifted its stake in Inozyme Pharma by 18.8% in the 3rd quarter. New York State Common Retirement Fund now owns 10,453 shares of the company’s stock valued at $121,000 after acquiring an additional 1,651 shares in the last quarter.

About Inozyme Pharma (Get Rating)

Inozyme Pharma, Inc, a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis.

Recommended Stories

Earnings History and Estimates for Inozyme Pharma (NASDAQ:INZY)

Receive News & Ratings for Inozyme Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inozyme Pharma and related companies with MarketBeat.com's FREE daily email newsletter.